Suchergebnisse - "Ward, Patrick J"

PubPharm (49)

1

Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer : Results from Dose Exploration in a First-in-Human Study

enthalten in: Cancer discovery | 2024

von Kelly, W. | Danila, D. | Lin, C. | +18

CommentIn: Cancer Discov. 2024 Jan 12;14(1):20-22. - PMID 38213299

2

Corrigendum to "Extent and implications of omitted ties on network measures in a longitudinal social network survey of people who use drugs" [Drug Alcohol Depend. 238 (2022) 109554

enthalten in: Drug and alcohol dependence | 2023

von Upton, E. | Rudolph, A. | Ward, P. | +2

ErratumFor: Drug Alcohol Depend. 2022 Sep 1;238:109554. - PMID 35850026

3

Deep Neural Networks for Fine-Grained Surveillance of Overdose Mortality

enthalten in: American journal of epidemiology | 2023

von Ward, P. | Young, A. | Slavova, S. | +4

4

Swimming performance traits of twenty-one Australian fish species: a fish passage management tool for use in modified freshwater systems

enthalten in: bioRxiv.org | 2022

von Watson, J. | Goodrich, H. | Cramp, R. | +4

5

Extent and implications of omitted ties on network measures in a longitudinal social network survey of people who use drugs

enthalten in: Drug and alcohol dependence | 2022

von Upton, E. | Rudolph, A. | Ward, P. | +2

ErratumIn: Drug Alcohol Depend. 2023 Nov 1;252:110901. - PMID 37481411

6

Correction to : Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

enthalten in: Breast cancer research and treatment | 2022

von Geyer, C. | Bandos, H. | Rastogi, P. | +15

ErratumFor: Breast Cancer Res Treat. 2022 Jun;193(3):555-564. - PMID 35230585

7

Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer : the NSABP B-36 trial (NRG Oncology)

enthalten in: Breast cancer research and treatment | 2022

von Geyer, C. | Bandos, H. | Rastogi, P. | +15

ErratumIn: Breast Cancer Res Treat. 2022 May 4;:. - PMID 35507135

8

Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

enthalten in: Breast cancer research and treatment | 2022

von Geyer, C. | Bandos, H. | Rastogi, P. | +15

9

Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

enthalten in: Breast cancer research and treatment | 2022

von Geyer, C. | Bandos, H. | Rastogi, P. | +15

10

Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

enthalten in: Breast cancer research and treatment | 2022

von Geyer, C. | Bandos, H. | Rastogi, P. | +15

1
2
3
4
5
Nächster »
[5]